Non-profit model urged to fix global health funding crisis

The global health community is grappling with recurring crises as major donors, notably the U.S. government, announce funding cuts. This has sent ripples through organizations dedicated to developing medicines for the world's poorest populations, leading to frozen research pipelines and the continued unchecked spread of diseases that have historically hindered prosperity in low- and middle-income countries.

The current pharmaceutical development model operates on commercial logic, demanding substantial upfront investment only when a financial return is guaranteed. This system inherently neglects diseases that affect populations unable to pay, creating a significant gap in essential treatments. For instance, since 2008, the U.S. Food and Drug Administration (FDA) has approved over 1,000 new chemical entities, but only 13 targeted neglected diseases, malaria, or tuberculosis. This starkly contrasts with the development of medicines for profitable markets, highlighting a failure of public health systems to assume responsibility for these neglected areas.

Organizations like Medicines Development for Global Health (MDGH), the Drugs for Neglected Diseases initiative (DNDi), the Medicines for Malaria Venture (MMV), the Global Antibiotic Research and Development Partnership (GARDP), and the TB Alliance are caught in the consequences of this broken funding model. Despite efforts like donation programs and intellectual property sharing, industry contributions are often deemed insufficient, leading to antipathy and quiet withdrawals from some entities. The Japan Pharmaceutical Manufacturers Association has openly stated that current arrangements are unsustainable.

To address these persistent global health inequities, a permanent fix is urgently needed. The article proposes a non-profit medicine development model as a viable alternative. Such a model would prioritize public health needs over commercial returns, ensuring that life-saving and disease-eliminating treatments are developed and accessible to all, regardless of their ability to pay. This approach aims to rectify the imbalance where more resources are allocated to space exploration than to developing medicines for the world's most vulnerable populations.